MalnutritiOn assessment with biOelectrical impedaNce analysis in gastRic cancer patIentS undergoing multimodaltrEatment (MOONRISE)-Study protocol for a single-arm multicenter cross-sectional longitudinal study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 27 03 2023
accepted: 03 01 2024
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: epublish

Résumé

European data suggests that over 30% of gastric cancer (GC) patients are diagnosed with sarcopenia before surgery, while unintentional weight loss occurs in approximately 30% of patients following gastrectomy. Preoperative sarcopenia significantly increases the risk of major postoperative complications, and preoperative body weight loss remains a superior predictor of outcome and an independent prognostic factor for overall survival (OS) in patients with GC. A standardized approach of nutritional risk screening of GC patients is yet to be established. Therefore, the MOONRISE study aims to prospectively analyze the changes in nutritional status and body composition at each stage of multimodal treatment among GC patients from five Western expert centers. Specifically, we seek to assess the association between nutritional status and body composition on tumor response following neoadjuvant chemotherapy (NAC). Secondary outcomes of the study are treatment toxicity, postoperative complications, quality of life (QoL), and OS. Patients with locally advanced gastric adenocarcinoma scheduled for multimodal treatment will be included in the study. Four consecutive nutritional status assessments will be performed throughout the treatment. The following study was registered in ClinicalTrials.gov (Identifier: NCT05723718) and will be conducted in accordance with the STROBE statement. The anticipated duration of the study is 12-24 months, depending on the recruitment status. Results of this study will reveal whether nutritional status and body composition assessment based on BIA will become a validated and objective tool to support clinical decisions in GC patients undergoing multimodal treatment.

Identifiants

pubmed: 38319910
doi: 10.1371/journal.pone.0297583
pii: PONE-D-23-08608
doi:

Banques de données

ClinicalTrials.gov
['NCT05723718']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0297583

Informations de copyright

Copyright: © 2024 Pelc et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Zuzanna Pelc (Z)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Katarzyna Sędłak (K)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Radosław Mlak (R)

Department of Human Physiology, Medical University of Lublin, Lublin, Poland.

Katarzyna Chawrylak (K)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Katarzyna Mielniczek (K)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Magdalena Leśniewska (M)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Magdalena Skórzewska (M)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Magdalena Kwietniewska (M)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Iwona Paśnik (I)

Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland.

Katarzyna Gęca (K)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Pieter van der Sluis (P)

Upper Gastrointestinal Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.

Tomasz Banasiewicz (T)

Department of General, Endocrynological Surgery and Gastrointestinal Oncology, Institute of Surgery, Poznan University of Medical Sciences, Poznań, Polska.

Michał Pędziwiatr (M)

2nd Department of Surgery, Jagiellonian University Medical College, Kraków, Polska.

Wojciech P Polkowski (WP)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Timothy M Pawlik (TM)

Department of Surgery, The Ohio State University Wexner Medical Center and James Cancer Center, Columbus, Ohio, United States of America.

Teresa Małecka-Massalska (T)

Department of Human Physiology, Medical University of Lublin, Lublin, Poland.

Karol Rawicz-Pruszyński (K)

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.

Classifications MeSH